Abstract: Objective：To research the clinical effect of GM-1 combined with EPO on hypoxic ischemic encephalopathy （HIE）of newborn.Methods：78 cases of HIE in our hospital from 2015 to 2016 were randomly divided into research group and control group，39 cases in each group. Patients in research group were given GM-1 and EPO；Patients in control group were given GM-1. Besides，patients in both groups were given conventional therapy.Neurological scores，NBNA，CDCC，Gesell development scores and clinical effect evaluation were performed on all the newborn patients of the two groups.Results：Total effective rate was 94.9% of research group， and 82.1% of the control group， with statistically significant difference(P＜0.05).At the 7th day after born，the neurological scores of the research group was (2.67±0.42)points， lower than （2.94±0.81）points in the control group.The difference was statistically significant(P＜0.05).At the 7th，14th，28th day after born，the NBNA scores of the research group were higher than that of the control group.The difference was statistically significant(P＜0.05).The CDCC scores at the 3th，6th month after born，and the Gesell score at the 10th month after born in the research group was higher than those in the control group (P＜0.05).Conclusion：GM-1 combined with EPO on the treatment of HIE is of high clinical efficiency and of great clinical value to generalize.